Arcus Biosciences
Stock Forecast, Prediction & Price Target
Arcus Biosciences (RCUS) stock Price Target by analysts
$32.5
Potential upside: 231.63%
Arcus Biosciences price prediction
What is Arcus Biosciences stock analysts` prediction?
Arcus Biosciences stock forecast: Based on 4 Wall Street analysts` predicted price targets for Arcus Biosciences in the last 3 months, the avarage price target is $32.5, with a high forecast of $NaN. The average price target represents a 231.63% change from the last price of $9.8.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Arcus Biosciences stock Price Target by analysts
Full breakdown of analysts given Arcus Biosciences price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Yigal Nochomovitz Citigroup | 0% 0/1 | 11 months ago | $46 369.38% upside | $17.42 | TheFly | Previous targets (0) |
Emily Bodnar H.C. Wainwright | 0% 0/1 | 11 months ago | $20 104.08% upside | $18.44 | StreetInsider | Previous targets (0) |
Eva Fortea Verdejo Wells Fargo | 0% 0/1 | 12 months ago | $29 195.91% upside | $18.08 | Benzinga | Previous targets (0) |
Judah Frommer Morgan Stanley | 0% 0/1 | 12 months ago | $35 257.14% upside | $18.08 | Benzinga | Previous targets (0) |
Jason Zemansky Bank of America Securities | 0% 0/1 | about 1 year ago | $23 134.69% upside | $13.69 | StreetInsider | Previous targets (0) |
Peter Lawson Barclays | 0% 0/2 | about 1 year ago | $25 155.10% upside | $14 | StreetInsider | Previous targets (1) |
Asthika Goonewardene Truist Financial | 0% 0/1 | over 1 year ago | $44 348.97% upside | $16.45 | StreetInsider | Previous targets (0) |
Peter Lawson Barclays | 0% 0/2 | over 1 year ago | $35 257.14% upside | $16.15 | StreetInsider | Previous targets (1) |
Unknown Citigroup | N/A | almost 3 years ago | $42 328.57% upside | $20.66 | Benzinga | N/A |
Unknown Citigroup | N/A | almost 3 years ago | $37 277.55% upside | $27 | Benzinga | N/A |
Robert Driscoll Wedbush | 0% 0/1 | over 3 years ago | $42 328.57% upside | $24.01 | TheFly | Previous targets (0) |
Arcus Biosciences Financial Estimates
Arcus Biosciences Revenue Estimates
Arcus Biosciences EBITDA Estimates
Arcus Biosciences Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $382.88M N/A | $112M -70.74% | $117M 4.46% | Avg: $171.86M Low: $43.99M High: $296.23M avg. 46.89% | Avg: $325.82M Low: $134.13M High: $610.05M avg. 89.58% | Avg: $341.74M Low: $140.69M High: $639.86M avg. 4.88% | Avg: $815.69M Low: $335.80M High: $1.52B avg. 138.68% |
Net Income
% change YoY
| $53M N/A | $-267M -603.77% | $-307M -14.98% | Avg: $-423.83M Low: $-471.38M High: $-241.24M avg. -38.05% | Avg: $-357.73M Low: $-469.90M High: $-95.46M avg. 15.59% | Avg: $-251.73M Low: $-537.20M High: $-59.20M avg. 29.63% | Avg: $78.79M Low: $18.53M High: $168.15M avg. 131.30% |
EBITDA
% change YoY
| $54.90M N/A | $-264M -580.83% | $-283M -7.19% | Avg: $-132.56M Low: $-228.49M High: $-33.93M avg. 53.15% | Avg: $-251.31M Low: $-470.54M High: $-103.46M avg. -89.58% | Avg: $-263.59M Low: $-493.53M High: $-108.51M avg. -4.88% | Avg: $-629.16M Low: $-1.17B High: $-259.01M avg. -138.68% |
EPS
% change YoY
| $0.76 N/A | -$3.71 -588.15% | -$4.15 -11.85% | Avg: -$4.64 Low: -$6.37 High: -$3.26 avg. -11.71% | Avg: -$3.68 Low: -$6.35 High: -$1.29 avg. 20.58% | Avg: -$3.4 Low: -$7.26 High: -$0.8 avg. 7.59% | Avg: $1.06 Low: $0.25 High: $2.27 avg. 131.30% |
Operating Expenses
% change YoY
| $328.63M N/A | $392M 19.28% | $457M 16.58% | Avg: $149.39M Low: $38.24M High: $257.50M avg. -67.31% | Avg: $283.22M Low: $116.59M High: $530.28M avg. 89.58% | Avg: $297.06M Low: $122.29M High: $556.20M avg. 4.88% | Avg: $709.04M Low: $291.89M High: $1.32B avg. 138.68% |
FAQ
What is Arcus Biosciences stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 34.61% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is -471.38M, average is -423.83M and high is -241.24M.
What is Arcus Biosciences stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 70.01% in 2025-2028.
We have gathered data from 7 analysts. Their low revenue estimate is $43.99M, average is $171.86M and high is $296.23M.
What is Arcus Biosciences stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 36.94% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is -$6.37, average is -$4.64 and high is $-3.26.
What is the best performing analyst?
In the last twelve months 4 analysts have been covering Arcus Biosciences stock. The most successful analyst is Yigal Nochomovitz.